ICOS binding proteins
The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
1. An ICOS binding protein or antigen binding portion thereof comprising a V H domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:7; and a V L domain comprising an amino acid sequence at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:8 wherein said ICOS binding protein or antigen binding portion thereof specifically binds to human ICOS.
2. The ICOS binding protein or antigen binding portion thereof of claim 1 comprising heavy chain CDRs having the amino acid sequences set forth in SEQ ID NO:1; SEQ ID NO:2; and SEQ ID NO:3 and light chain CDRs having the amino acid sequences set forth in SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6.
3. The ICOS binding protein or antigen binding portion thereof of claim 1 comprising a V H domain comprising the amino acid sequence set forth in SEQ ID NO:7; and a V L domain comprising the amino acid sequence set forth in SEQ ID NO:8.
4. The ICOS binding protein or antigen binding portion thereof of claim 1 that is an agonist to human ICOS.
5. The ICOS binding protein or antigen binding portion thereof of claim 1 further comprising an IgG4 isotype scaffold or a variant thereof.
6. The ICOS binding protein or antigen binding portion thereof of claim 1 further comprising a scaffold, wherein the scaffold is a human IgG4 isotype and comprises an Fc region comprising a S228P mutation and a L235E mutation.
7. The ICOS binding protein or antigen binding portion thereof of claim 1 wherein said ICOS binding protein is a humanized monoclonal antibody.
8. A pharmaceutical composition comprising the ICOS binding protein or antigen binding portion thereof of claim 1 and a pharmaceutically acceptable carrier.
9. A polynucleotide encoding the ICOS binding protein or antigen binding portion thereof of claim 1 .
10. An isolated humanized monoclonal antibody comprising a V H domain comprising the amino acid sequence set forth in SEQ ID NO:7; a V L domain comprising the amino acid sequence set forth in SEQ ID NO:8; and a human IgG4 scaffold, wherein said antibody specifically binds to human ICOS.
11. The isolated humanized monoclonal antibody of claim 10 wherein the human IgG4 scaffold comprises an Fc region comprising a S228P mutation and a L235E mutation.
12. A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.
13. An isolated humanized monoclonal antibody comprising a V H domain comprising an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:7; and a V L domain comprising an amino acid sequence at least 99% identical to the amino acid sequence as set forth in SEQ ID NO:8 wherein said antibody specifically binds to human ICOS.
14. The antibody of claim 13 comprising heavy chain CDRs having the amino acid sequences set forth in SEQ ID NO:1; SEQ ID NO:2; and SEQ ID NO:3 and light chain CDRs having the amino acid sequences set forth in SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6.
15. The antibody of claim 13 that is an agonist to human ICOS.
16. The antibody of claim 13 further comprising an IgG4 isotype scaffold or a variant thereof.
17. The antibody of claim 13 further comprising a scaffold, wherein the scaffold is a human IgG4 isotype and comprises an Fc region comprising a S228P mutation and a L235E mutation.
18. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18 further comprising at least one immunomodulatory agent.
20. The pharmaceutical composition of claim 19 wherein said immunomodulatory agent is selected from ipilimumab, nivolumab, and pembrolizumab.
21. The pharmaceutical composition of claim 18 further comprising at least one immunostimulatory agent.
22. The pharmaceutical composition of claim 21 wherein said immunostimulatory agent is CRX-601 having the structure: